Abstract
Adenosine receptors belong to the family of G protein-coupled receptors. Four distinct subtypes are known, termed A1, A2A, A2B and A3. Adenosine is an important signaling molecule which is released under inflammatory conditions. It can show antiinflammatory as well as proinflammatory activities, and the contribution of the specific adenosine receptor subtypes in various cells, tissues and organs is complex. Agonists selective for adenosine A1 receptors show antinociceptive activity and are active in animal models of neuropathic and inflammatory pain. Adenosine A2A receptor agonists are potent antiinflammatory drugs. A2A-selective antagonists have shown antihyperalgesic activity in animal models of inflammatory pain. For A2B agonists as well as A2B antagonists antiinflammatory activity has been postulated. Selective A2B antagonists were shown to decrease (inflammatory) pain, and are promising candidates for the treatment of asthma. Adenosine A3 receptor agonists appear to be proinflammatory, while there is evidence for an antiinflammatory effect of A3 antagonists. There are some contradictory findings, and A 3 agonists are being developed for the treatment of inflammatory diseases such as arthritis. Indirect mechanisms increasing the extracellular concentration of adenosine using adenosine kinase inhibitors, adenosine deaminase inhibitors or adenosine uptake inhibitors, or increasing the potency of adenosine at the A1 receptor subtype by allosteric modulators lead to potent antinociceptive and antiinflammatory activity. The advantage of indirectly acting drugs may be their site- and event-specific action since they are only active where adenosine has been released. In the past decade considerable progress has been made towards the identification of novel lead structures and the development of potent and selective ligands for all four adenosine receptor subtypes. A large number of patents has recently been filed and the field is finally in the process of translating many years of basic science into therapeutic application. This review article will focus on compounds published or patented within the past three years.
Keywords: Xanthine antagonist, Pyridazinone derivatives, pyrazine derivatives, inflammation, MRE-0094, Asthma
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Volume: 6 Issue: 13
Author(s): Rhalid Akkari, Joachim C. Burbiel, Jorg Hockemeyer and Christa E. Muller
Affiliation:
Keywords: Xanthine antagonist, Pyridazinone derivatives, pyrazine derivatives, inflammation, MRE-0094, Asthma
Abstract: Adenosine receptors belong to the family of G protein-coupled receptors. Four distinct subtypes are known, termed A1, A2A, A2B and A3. Adenosine is an important signaling molecule which is released under inflammatory conditions. It can show antiinflammatory as well as proinflammatory activities, and the contribution of the specific adenosine receptor subtypes in various cells, tissues and organs is complex. Agonists selective for adenosine A1 receptors show antinociceptive activity and are active in animal models of neuropathic and inflammatory pain. Adenosine A2A receptor agonists are potent antiinflammatory drugs. A2A-selective antagonists have shown antihyperalgesic activity in animal models of inflammatory pain. For A2B agonists as well as A2B antagonists antiinflammatory activity has been postulated. Selective A2B antagonists were shown to decrease (inflammatory) pain, and are promising candidates for the treatment of asthma. Adenosine A3 receptor agonists appear to be proinflammatory, while there is evidence for an antiinflammatory effect of A3 antagonists. There are some contradictory findings, and A 3 agonists are being developed for the treatment of inflammatory diseases such as arthritis. Indirect mechanisms increasing the extracellular concentration of adenosine using adenosine kinase inhibitors, adenosine deaminase inhibitors or adenosine uptake inhibitors, or increasing the potency of adenosine at the A1 receptor subtype by allosteric modulators lead to potent antinociceptive and antiinflammatory activity. The advantage of indirectly acting drugs may be their site- and event-specific action since they are only active where adenosine has been released. In the past decade considerable progress has been made towards the identification of novel lead structures and the development of potent and selective ligands for all four adenosine receptor subtypes. A large number of patents has recently been filed and the field is finally in the process of translating many years of basic science into therapeutic application. This review article will focus on compounds published or patented within the past three years.
Export Options
About this article
Cite this article as:
Akkari Rhalid, Burbiel C. Joachim, Hockemeyer Jorg and Muller E. Christa, Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs, Current Topics in Medicinal Chemistry 2006; 6 (13) . https://dx.doi.org/10.2174/15680266106061375
DOI https://dx.doi.org/10.2174/15680266106061375 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Overview of the Primary Structure, Tissue-Distribution, and Functions of Tachykinins and their Receptors
Current Drug Targets Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacogenetics of the Antiplatelet Effect of Aspirin
Current Pharmaceutical Design Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry HCV and Autoimmunity
Current Pharmaceutical Design Enteric Coated Guar Gum Microspheres of Ornidazole for Colonic Delivery
Current Nanoscience The Role of Stress in Inflammatory Bowel Diseases
Current Pharmaceutical Design An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future
Current Pharmaceutical Design Patent Selections:
Recent Patents on Drug Delivery & Formulation Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Gaultheria Ethnobotany and Bioactivity: Blueberry Relatives with Anti-inflammatory, Antioxidant, and Anticancer Constituents
Current Medicinal Chemistry Meet Our Regional Editor
Applied Clinical Research, Clinical Trials and Regulatory Affairs Volatile Oil Containing Plants as Phytopharmaceuticals to Treat Psoriasis: A Review
Current Pharmaceutical Biotechnology Pathophysiology of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology